LFCR (Lifecore Biomedical) Notes Receivable: $0.00 Mil (As of Mar. 2026)


LFCR Lifecore Biomedical Inc LFCR
55 GF Score
Price $4.97
GF Value $6.52
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Lifecore Biomedical Notes Receivable?

Lifecore Biomedical LFCR -3.78% 55 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates LFCR with a GF Score™ of 55/100 and a GF Value™ of $6.52 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Lifecore Biomedical's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Lifecore Biomedical's annual Notes Receivable stayed the same from May. 2023 ($0.00 Mil) to May. 2024 ($0.00 Mil) but then increased from May. 2024 ($0.00 Mil) to May. 2025 ($8.00 Mil).

Lifecore Biomedical Notes Receivable Related Terms

Lifecore Biomedical Notes Receivable Historical Data

* Premium members only.

The historical data trend for Lifecore Biomedical's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical Notes Receivable Chart

Lifecore Biomedical Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 8.00

Lifecore Biomedical Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 8.00 0.00 0.00 0.00
LFCR
55GF Score
Lifecore Biomedical Inc LFCR
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lifecore Biomedical Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Lifecore Biomedical (LFCR) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Lifecore Biomedical and its competitors.
Is Lifecore Biomedical's Notes Receivable too high?
Lifecore Biomedical's current Notes Receivable is $0.00 Mil. Overall, Lifecore Biomedical has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Notes Receivable compare to ANIK and DERM?
Lifecore Biomedical's Notes Receivable of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Lifecore Biomedical and its competitors. Lifecore Biomedical's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.52, compared to a current price of $4.97 — trading 23.8% below its estimated fair value. The current Notes Receivable is $0.00 Mil. Lifecore Biomedical's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lifecore Biomedical (LFCR) Overvalued in 2026?

Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued. The current stock price of $4.97 is trading 23.8% below its estimated GF Value™ of $6.52. GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.

Key valuation signals for LFCR:

  • Notes Receivable: $0.00 Mil
  • GF Value™: $6.52 vs. price of $4.97 (23.8% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lifecore Biomedical Business Description

Other Exchanges LDE:Germany
Address 3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
55GF Score

Get the complete analysis for LFCR

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.97
Price
$6.52
GF Value